Sign in

NCT07645716Not yet recruiting

Evaluation of Interactions and Group Processes in Multidisciplinary Tumor Boards in Gynecologic Oncology

Group Dynamics Evaluation in ginecOlogic muLtidisciplinary Tumor boarDs

Source: ClinicalTrials.gov · Last updated 12 Jun 2026

Brief summary (registry, in English)

Study Title Group Dynamics Evaluation in Gynecologic Multidisciplinary Tumor Boards - GOLD Study Background and Rationale Multidisciplinary Tumor Boards are central to complex oncologic decision-making. In gynecologic oncology, clinical decisions often require the integration of knowledge from different specialties, including surgery, medical oncology, radiology, pathology, radiation oncology, and other relevant disciplines. These teams function not only as groups of specialists but also as collective decision-making systems, where communication, collaboration, information sharing, psychological safety, and group dynamics may influence the quality of clinical discussion and final recommendations. Study Objective The GOLD Study aims to investigate the decision-making process and group dynamics within ovarian and uterine cancer Multidisciplinary Tumor Boards. The study will assess how communication patterns, collaboration, minority dissent, team cohesion, team learning, task interdependence, collective information processing, individual information processing, and psychological safety contribute to Tumor Board performance. Study Design This is a single-center, prospective, longitudinal observational study involving physicians participating in ovarian and uterine cancer Multidisciplinary Tumor Boards, either in person or online. Methods At the end of each Tumor Board meeting, participating physicians will complete an online survey using Microsoft Forms. The questionnaire was developed within a scientific collaboration with the Department of Business and Management of LUISS Guido Carli University and includes validated measurement scales derived from the literature. In addition, data on team composition and participation will be collected for each meeting. Statistical Analysis Survey data and participation data will be analyzed using descriptive statistics, inferential methods, and social network analysis. Network measures such as density and centralization indices will be used to evaluate the structure of interactions and participation over time. Statistical analyses will be performed using Stata, R, and UCINET where appropriate. Target Population and Sample Size The target population includes physicians involved in the clinical decision-making process during ovarian and uterine cancer Tumor Boards. A total of approximately 400 questionnaires is planned, based on the rule of thumb of at least 10 respondents per questionnaire variable. Study Duration The expected study duration is six months.

Status (registry)
Not yet recruiting
Study type
Observational
Enrollment
400 (estimated)
First submitted
9 Jun 2026
Start date
13 Jul 2026
Primary completion date
31 Jan 2027
Lead sponsor
Fondazione Policlinico Universitario Agostino Gemelli IRCCS
NCT number
NCT07645716

What you commit to

  • Study type: Observational
  • Planned participants: 400
  • From 13 Jul 2026 to the primary completion date, 31 Jan 2027
  • 1 site in 1 country
  • Visits and tests: ask the trial team, the registry does not list them

Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.

Who cannot take part

Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.

Other illness

  • Partial attendance at the ovarian and uterine cancer multidisciplinary tumor board session.

Other

  • Trainees or other attendees not directly involved in the clinical decision-making process.
  • Physicians whose specialty contribution consists of occasional consultation for less than 50% of the study period.
  • Incomplete survey completion.
  • If more than one member represents the same specialty or role, participants with lower participation in the clinical decision-making process may be excluded.

Who the study is looking for

  • Physicians participating in the clinical decision-making process within ovarian and uterine cancer multidisciplinary tumor board meetings.
  • Participation in the full tumor board session.
  • Participation either in person or online.
  • Representation of at least one relevant specialty or role involved in the clinical decision-making process.

Age in the registry: 18 years to - · Sex: All

Full criteria on ClinicalTrials.gov

Sites (1)

Sites in registry order. Save your city in your profile to sort them by distance.

SiteCityCountrySite status
Fondazione Policlinico Universitario A. Gemelli IRCCS, UOC Ginecologia Oncologica
Coordinator of this site? Confirm its status
RomaItalyUnknown status

This page is information, not medical advice. Discuss any trial with your doctor.